Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if NAMS is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
52 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 13 days ago
Red flags: 1
195 filers reported a long position in NAMS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $613M | 18.1M | +6.8% |
| Capital World Investors | $414.5M | 12.2M | +10.1% |
| FMR LLC | $350.4M | 10.3M | +18% |
| RA CAPITAL MANAGEMENT, L.P. | $323.7M | 9.6M | Unchanged |
| FCPM III SERVICES B.V. | $287.7M | 8.5M | -7.7% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $144.5M | 4.3M | Unchanged |
| VIKING GLOBAL INVESTORS LP | $142.5M | 4.2M | Unchanged |
| Bain Capital Life Sciences Investors, LLC | $129M | 3.8M | -47.9% |
| MAVERICK CAPITAL LTD | $110.7M | 3.3M | +49.5% |
| Duquesne Family Office LLC | $104M | 3.1M | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.